JP2018535224A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018535224A5 JP2018535224A5 JP2018526543A JP2018526543A JP2018535224A5 JP 2018535224 A5 JP2018535224 A5 JP 2018535224A5 JP 2018526543 A JP2018526543 A JP 2018526543A JP 2018526543 A JP2018526543 A JP 2018526543A JP 2018535224 A5 JP2018535224 A5 JP 2018535224A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- nanoparticle
- composition according
- patient
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 37
- 239000002105 nanoparticle Substances 0.000 claims 36
- 108090000765 processed proteins & peptides Proteins 0.000 claims 13
- 239000011859 microparticle Substances 0.000 claims 11
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 239000010419 fine particle Substances 0.000 claims 5
- 239000013543 active substance Substances 0.000 claims 4
- 206010022000 influenza Diseases 0.000 claims 4
- 102000006495 integrins Human genes 0.000 claims 4
- 108010044426 integrins Proteins 0.000 claims 4
- 208000024827 Alzheimer disease Diseases 0.000 claims 3
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 3
- 206010063094 Cerebral malaria Diseases 0.000 claims 3
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 3
- 229920006022 Poly(L-lactide-co-glycolide)-b-poly(ethylene glycol) Polymers 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 230000033115 angiogenesis Effects 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims 2
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 2
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 2
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims 2
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 239000003443 antiviral agent Substances 0.000 claims 2
- 230000008499 blood brain barrier function Effects 0.000 claims 2
- 210000001218 blood-brain barrier Anatomy 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- 229920000642 polymer Polymers 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 230000008685 targeting Effects 0.000 claims 2
- 230000002792 vascular Effects 0.000 claims 2
- 201000006474 Brain Ischemia Diseases 0.000 claims 1
- 206010048962 Brain oedema Diseases 0.000 claims 1
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 1
- 208000031124 Dementia Alzheimer type Diseases 0.000 claims 1
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 241001115402 Ebolavirus Species 0.000 claims 1
- 206010061192 Haemorrhagic fever Diseases 0.000 claims 1
- 206010050513 Metastatic renal cell carcinoma Diseases 0.000 claims 1
- 206010030113 Oedema Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims 1
- 206010064930 age-related macular degeneration Diseases 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 230000000078 anti-malarial effect Effects 0.000 claims 1
- 230000000840 anti-viral effect Effects 0.000 claims 1
- 239000003430 antimalarial agent Substances 0.000 claims 1
- 229940041181 antineoplastic drug Drugs 0.000 claims 1
- 210000004204 blood vessel Anatomy 0.000 claims 1
- 208000006752 brain edema Diseases 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 201000011190 diabetic macular edema Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000008482 dysregulation Effects 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- OOYGSFOGFJDDHP-KMCOLRRFSA-N kanamycin A sulfate Chemical group OS(O)(=O)=O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N OOYGSFOGFJDDHP-KMCOLRRFSA-N 0.000 claims 1
- 230000003902 lesion Effects 0.000 claims 1
- 230000035168 lymphangiogenesis Effects 0.000 claims 1
- 229920002521 macromolecule Polymers 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 230000000926 neurological effect Effects 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 239000000863 peptide conjugate Substances 0.000 claims 1
- 208000004644 retinal vein occlusion Diseases 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562257569P | 2015-11-19 | 2015-11-19 | |
| US62/257,569 | 2015-11-19 | ||
| PCT/US2016/062816 WO2017087825A1 (en) | 2015-11-19 | 2016-11-18 | Peptides with anti-angiogenic, anti-lymphangiogenic, and anti-edemic properties and nanoparticle formulations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018535224A JP2018535224A (ja) | 2018-11-29 |
| JP2018535224A5 true JP2018535224A5 (OSRAM) | 2019-12-26 |
Family
ID=58717907
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018526543A Pending JP2018535224A (ja) | 2015-11-19 | 2016-11-18 | 抗血管新生、抗リンパ管新生及び抗浮腫特性を有するペプチド及びナノ粒子製剤 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20180339024A1 (OSRAM) |
| EP (1) | EP3377080B1 (OSRAM) |
| JP (1) | JP2018535224A (OSRAM) |
| KR (1) | KR20180081608A (OSRAM) |
| CN (1) | CN108883150A (OSRAM) |
| AU (1) | AU2016358125A1 (OSRAM) |
| BR (1) | BR112018010052A2 (OSRAM) |
| CA (1) | CA3005284A1 (OSRAM) |
| IL (1) | IL259376A (OSRAM) |
| MX (1) | MX2018006194A (OSRAM) |
| SG (2) | SG10202004259PA (OSRAM) |
| WO (1) | WO2017087825A1 (OSRAM) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112019021056B1 (pt) | 2017-04-06 | 2022-11-22 | Sustain Holdings, Llc | Usos de uma composição que compreende um peptídeo mimético de colágeno para o tratamento ou a prevenção de uma doença, distúrbio ou ferida ocular |
| WO2019028427A1 (en) | 2017-08-03 | 2019-02-07 | Asclepix Therapeutics, Llc. | METHODS OF IDENTIFYING AND PREPARING PHARMACEUTICAL AGENTS TO ACTIVATE TIE2 RECEPTOR |
| US20210113654A1 (en) * | 2018-05-31 | 2021-04-22 | Yale University | Methods and Compositions to Alleviate Vascular Permeability |
| JP7650074B2 (ja) * | 2019-03-26 | 2025-03-24 | アスクレピクス セラピューティクス インコーポレイテッド | 眼疾患を治療するための組成物及び方法 |
| US11389513B2 (en) | 2019-04-22 | 2022-07-19 | Sustain Holdings, Llc | Collagen peptide-based medicament compositions and devices and methods of production and use thereof |
| US20230086800A1 (en) * | 2020-03-06 | 2023-03-23 | The Board Of Trustees Of The Leland Stanford Junior University | Antibody fragments conjugated to peg-plga nanoparticles improve immunotherapy against cancer cells |
| GB202004514D0 (en) | 2020-03-27 | 2020-05-13 | Inst De Medicina Molecular Joaeo Lobo Antunes | Treatment of Immunosuppressive Cancer |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE318832T1 (de) | 1990-06-11 | 2006-03-15 | Gilead Sciences Inc | Verfahren zur vervendung von nukleinsäureliganden |
| SE9400088D0 (sv) | 1994-01-14 | 1994-01-14 | Kabi Pharmacia Ab | Bacterial receptor structures |
| ES2210306T3 (es) | 1994-07-20 | 2004-07-01 | The General Hospital Corporation | Sistemas de trampa para interacciones, para detectar interacciones de proteinas. |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| AUPP221098A0 (en) | 1998-03-06 | 1998-04-02 | Diatech Pty Ltd | V-like domain binding molecules |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| DK2230303T3 (da) | 1999-05-05 | 2013-04-15 | Phylogica Ltd | Isolering af biologiske modulatorer fra biodiverse genfragment-biblioteker |
| EP1181358B1 (en) | 1999-05-26 | 2010-11-17 | Next Biomed Technologies NBT Oy | Methods and materials for generating sh3 domains with tailored binding properties |
| SE0001877D0 (sv) | 2000-05-22 | 2000-05-22 | Klaus Mosbach | Molecular imprinting |
| JP5291279B2 (ja) | 2000-09-08 | 2013-09-18 | ウニヴェルジテート・チューリッヒ | 反復モジュールを含む反復タンパク質の集合体 |
| DE10053224A1 (de) | 2000-10-26 | 2002-05-08 | Univ Goettingen Georg August | Verfahren zur Exposition von Peptiden und Polypeptiden auf der Zelloberfläche von Bakterien |
| US20040132094A1 (en) | 2000-12-13 | 2004-07-08 | Michael Etzerodt | Combinatorial libraries of proteins having the scaffold structure of c-type lectinlike domains |
| JP2005508623A (ja) | 2001-08-30 | 2005-04-07 | バイオレクシス ファーマシューティカル コーポレイション | 改変されたトランスフェリン融合タンパク質 |
| JP5376747B2 (ja) | 2002-10-02 | 2013-12-25 | カタリスト バイオサイエンシーズ， インコーポレイテッド | 改変された特異性を有するプロテアーゼを作製する方法およびスクリーニングする方法 |
| WO2004063337A2 (en) | 2003-01-07 | 2004-07-29 | Dyax Corporation | Kunitz domain library |
| US20060008844A1 (en) | 2004-06-17 | 2006-01-12 | Avidia Research Institute | c-Met kinase binding proteins |
| DE102004049479A1 (de) | 2004-10-11 | 2006-04-13 | Scil Proteins Gmbh | Proteinkonjugate zur Verwendung in Therapie, Diagnose und Chromatographie |
| EP1892248A1 (en) | 2006-08-21 | 2008-02-27 | Eidgenössische Technische Hochschule Zürich | Specific and high affinity binding proteins comprising modified SH3 domains of FYN kinase |
| WO2008085828A2 (en) * | 2007-01-03 | 2008-07-17 | The Johns Hopkins University | Peptide modulators of angiogenesis and use thereof |
| WO2008151088A2 (en) | 2007-06-01 | 2008-12-11 | University Of Maryland, Baltimore | Immunoglobulin constant region fc receptor binding agents |
| US9051349B2 (en) | 2007-11-21 | 2015-06-09 | Alba Therapeutics Corporation | Larazotide acetate compositions |
| WO2010132879A2 (en) * | 2009-05-15 | 2010-11-18 | The Johns Hopkins University | Multicomponent degradable cationic polymers |
| WO2011084509A1 (en) * | 2009-12-15 | 2011-07-14 | Massachusetts Institute Of Technology | Endothelial basement membrane targeting peptide ligands |
| WO2012079088A2 (en) * | 2010-12-10 | 2012-06-14 | The Johns Hopkins University | Mimetic peptides derived from collagen type iv and their use for treating angiogenesis- and lymphangiogenesis- dependent diseases |
| WO2013025861A1 (en) * | 2011-08-17 | 2013-02-21 | Tufts Medical Center | Compounds and methods for augmenting permeability barriers |
| EP2788473A4 (en) | 2011-12-09 | 2015-11-11 | Univ Johns Hopkins | ARTIFICIAL ANTIGEN PRESENTING CELLS WITH DEFINED AND DYNAMIC FORM |
| WO2014018018A1 (en) * | 2012-07-24 | 2014-01-30 | Morehouse School Of Medicine | Composition and method for reducing tissue damage from inflammatory disorder or pathogenic infection |
| US9682143B2 (en) * | 2012-08-14 | 2017-06-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
| DK3003343T3 (da) * | 2013-06-07 | 2020-02-03 | Univ Johns Hopkins | Biomimetisk peptid og bionedbrydelig leveringsplatform til behandling af angiogenese- og lymfangiogeneseafhængige sygdomme |
| CN113667013B (zh) * | 2013-10-02 | 2024-04-09 | 免疫医疗有限责任公司 | 中和抗甲型流感抗体及其用途 |
-
2016
- 2016-11-18 KR KR1020187017365A patent/KR20180081608A/ko not_active Withdrawn
- 2016-11-18 EP EP16867239.2A patent/EP3377080B1/en active Active
- 2016-11-18 CN CN201680078709.0A patent/CN108883150A/zh active Pending
- 2016-11-18 WO PCT/US2016/062816 patent/WO2017087825A1/en not_active Ceased
- 2016-11-18 AU AU2016358125A patent/AU2016358125A1/en not_active Abandoned
- 2016-11-18 SG SG10202004259PA patent/SG10202004259PA/en unknown
- 2016-11-18 US US15/776,971 patent/US20180339024A1/en not_active Abandoned
- 2016-11-18 SG SG11201804003VA patent/SG11201804003VA/en unknown
- 2016-11-18 MX MX2018006194A patent/MX2018006194A/es unknown
- 2016-11-18 BR BR112018010052A patent/BR112018010052A2/pt not_active IP Right Cessation
- 2016-11-18 CA CA3005284A patent/CA3005284A1/en not_active Abandoned
- 2016-11-18 JP JP2018526543A patent/JP2018535224A/ja active Pending
-
2018
- 2018-05-15 IL IL259376A patent/IL259376A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018535224A5 (OSRAM) | ||
| Yasmin et al. | Novel drug delivery systems for inflammatory bowel disease | |
| Du et al. | Epidermal growth factor receptor-targeting peptide nanoparticles simultaneously deliver gemcitabine and olaparib to treat pancreatic cancer with breast cancer 2 (BRCA2) mutation | |
| Hu et al. | Nanoparticles targeting macrophages as potential clinical therapeutic agents against cancer and inflammation | |
| Hu et al. | Tumor microenvironment-mediated construction and deconstruction of extracellular drug-delivery depots | |
| Liu et al. | Prolonged ocular retention of mucoadhesive nanoparticle eye drop formulation enables treatment of eye diseases using significantly reduced dosage | |
| CN109890420B (zh) | 用于递送治疗剂的血小板组合物和方法 | |
| Sarvaiya et al. | Chitosan as a suitable nanocarrier material for anti-Alzheimer drug delivery | |
| Zou et al. | Targeted delivery of nano-PTX to the brain tumor-associated macrophages | |
| Pinto et al. | Targeted brain delivery nanoparticles for malignant gliomas | |
| US20170333365A1 (en) | Core-shell particle formulation for delivering multiple therapeutic agents | |
| JP2016155809A (ja) | 狭窄病変および血栓溶解療法のための剪断による制御放出 | |
| Zou et al. | Preparation, characterization, pharmacokinetic, and therapeutic potential of novel 6-mercaptopurine-loaded oral nanomedicines for acute lymphoblastic leukemia | |
| CN102970864A (zh) | 纳米颗粒药物组合物 | |
| JP2016521712A5 (OSRAM) | ||
| Guo et al. | Transferrin-functionalized microemulsions coloaded with coix seed oil and tripterine deeply penetrate to improve cervical cancer therapy | |
| Mishra et al. | Design of novel chemotherapeutic delivery systems for colon cancer therapy based on oral polymeric nanoparticles | |
| Jeswani et al. | Advances in the delivery of cancer therapeutics: a comprehensive review | |
| Joshi et al. | Inhibition of cancer cell metastasis by nanotherapeutics: current achievements and future trends | |
| Su et al. | Eudragit S100 coated nanodiamond-based nanoparticles as an oral chemo-photothermal delivery system for local treatment of colon cancer | |
| Panchangam et al. | Engineered nanoparticles for the delivery of anticancer therapeutics | |
| Yin et al. | Research advances in nanomedicine applied to the systemic treatment of colorectal cancer | |
| Yang et al. | Intravenous administration of scutellarin nanoparticles augments the protective effect against cerebral ischemia–reperfusion injury in rats | |
| Josowitz et al. | Polymer nanocarriers for targeted local delivery of agents in treating brain tumors | |
| Wahengbam et al. | Polymeric nanoparticles revolutionizing brain cancer therapy: a comprehensive review of strategies and advances |